Tag: Healthcare Stocks
-
HIMS Stock: GLP-1, The Fat People’s Drug Drama
HIMS stock collapsed after the GLP-1 controversy exposed weak margins and regulatory risks. Learn why investors should stay cautious.
-
Is investing in Novo Nordisk a mistake? The “Ozempic Patent Cliff” in India
Discover why the Ozempic patent expiring in India on March 20, 2026, is a major shift for investors. Learn which industries will win and why Novo Nordisk (NVO) faces a “generic tsunami.”